Heme oxygenase-1: Equally important in allogeneic hematopoietic stem cell transplantation and organ transplantation?
| Autor: | Carlijn Voermans, Myrddin W. Verheij, Sacha Zeerleder |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Immunology Graft vs Host Disease Hematopoietic stem cell transplantation 030230 surgery Liver transplantation Organ transplantation Kidney transplantation 03 medical and health sciences 0302 clinical medicine Cell-free heme medicine Immunology and Allergy Humans 610 Medicine & health Transplantation business.industry Hematopoietic Stem Cell Transplantation Organ Transplantation medicine.disease Heme oxygenase surgical procedures operative Heme oxygenase-1 Reperfusion Injury Allogeneic hematopoietic stem cell transplantation Pancreatic islet transplantation business Reperfusion injury 030215 immunology |
| DOI: | 10.48350/156858 |
| Popis: | Summary The intracellular enzyme heme oxygenase-1 (HO-1) is responsible for the degradation of cell-free (cf) heme. Cfheme, released upon cell damage and cell death from hemoglobin, mitochondria and myoglobin, functions as a powerful damage-associated molecular pattern (DAMP). Indeed, cfheme plays a role in a myriad of diseases characterized by (systemic) inflammation, and its rapid degradation by HO-1 is pivotal to maintain homeostasis. In the past decade, HO-1 has been extensively studied for its potential protective role in different transplantation settings, including allogeneic hematopoietic stem cell transplantation (HSCT), solid organ transplantation and pancreatic islet transplantation. These studies have shown that HO-1 can be induced by a wide range of molecules, and that induction of HO-1 has the potential to significantly reduce the incidence and severity of transplantation-related complications such as graft-versus-host disease (GvHD) and ischemia/reperfusion injury (IRI). As such, further investigation into the use of HO-1-inducing agents in human transplantation settings to facilitate the potential use of these agents in the clinic is warranted. In this review, we summarize the literature of the past 10 years on the role of HO-1 in allogeneic HSCT, solid organ transplantation (focusing on kidney and liver) and pancreatic islet transplantation. Furthermore, we provide a hypothesis about the way that HO-1 is able to provide protection against acute GvHD after allogeneic HSCT. A total of 48 research articles and 17 review articles were included in this review. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|